Los Angeles, California--(Newsfile Corp. - May 31, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Gossamer's IPO materials and public statements misled the market about its GB001 drug and its related clinical trials and studies. Novartis announced on December 16, 2019, that it was terminating development of its DP2 antagonist for asthma based on two failed phase 3 clinical trials. Based on these facts, the Company's public comments and IPO documents were false and materially misleading. When the market learned the truth about Gossamer, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56917